JP2020507332A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507332A5
JP2020507332A5 JP2019544614A JP2019544614A JP2020507332A5 JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5 JP 2019544614 A JP2019544614 A JP 2019544614A JP 2019544614 A JP2019544614 A JP 2019544614A JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5
Authority
JP
Japan
Prior art keywords
cancer
protein
pharmaceutical composition
composition according
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019544614A
Other languages
English (en)
Japanese (ja)
Other versions
JP7712060B2 (ja
JP2020507332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/053918 external-priority patent/WO2018149982A1/en
Publication of JP2020507332A publication Critical patent/JP2020507332A/ja
Publication of JP2020507332A5 publication Critical patent/JP2020507332A5/ja
Priority to JP2023133276A priority Critical patent/JP2023160838A/ja
Application granted granted Critical
Publication of JP7712060B2 publication Critical patent/JP7712060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019544614A 2017-02-17 2018-02-16 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ Active JP7712060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133276A JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17156718.3 2017-02-17
EP17156718 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133276A Division JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Publications (3)

Publication Number Publication Date
JP2020507332A JP2020507332A (ja) 2020-03-12
JP2020507332A5 true JP2020507332A5 (cg-RX-API-DMAC7.html) 2021-03-25
JP7712060B2 JP7712060B2 (ja) 2025-07-23

Family

ID=58094260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019544614A Active JP7712060B2 (ja) 2017-02-17 2018-02-16 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Country Status (13)

Country Link
US (1) US10980868B2 (cg-RX-API-DMAC7.html)
EP (1) EP3583200A1 (cg-RX-API-DMAC7.html)
JP (2) JP7712060B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240170928A (cg-RX-API-DMAC7.html)
CN (1) CN110291187A (cg-RX-API-DMAC7.html)
AU (1) AU2018222777B9 (cg-RX-API-DMAC7.html)
BR (1) BR112019016925A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050833A1 (cg-RX-API-DMAC7.html)
IL (1) IL268186A (cg-RX-API-DMAC7.html)
MX (1) MX2019009724A (cg-RX-API-DMAC7.html)
RU (1) RU2019125436A (cg-RX-API-DMAC7.html)
SG (1) SG11201907391SA (cg-RX-API-DMAC7.html)
WO (1) WO2018149982A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6947649B2 (ja) * 2015-06-18 2021-10-13 バクシム アクチェンゲゼルシャフト 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン
CA3109430A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
AU2021208400A1 (en) * 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
BR112014015706A2 (pt) * 2011-12-22 2020-10-27 Vaximm Ag método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a
BR112014033046A2 (pt) 2012-07-05 2017-06-27 Vaximm Ag linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01
CN105246496A (zh) * 2013-04-25 2016-01-13 万科斯蒙股份有限公司 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体
BR112016014405A2 (pt) * 2013-12-18 2018-02-20 Vaximm Gmbh cepa mutante atenuada de salmonela
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
JP6947649B2 (ja) 2015-06-18 2021-10-13 バクシム アクチェンゲゼルシャフト 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン
SG11201811258UA (en) 2016-07-13 2019-01-30 Vaximm Ag Process for the production of a dna vaccine for cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2020511139A5 (cg-RX-API-DMAC7.html)
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Piper et al. Glioma stem cells as immunotherapeutic targets: advancements and challenges
JP2020507332A5 (cg-RX-API-DMAC7.html)
JP6945301B2 (ja) Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン
RU2016129044A (ru) Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака
Fan et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
RU2015103758A (ru) Днк-вакцина для применения у пациентов с раком поджелудочной железы
US10987432B2 (en) Therapeutic delivery and expression system, methods and uses thereof
Kang et al. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects
Mei et al. Combining DNA vaccine and AIDA-1 in attenuated Salmonella activates tumor-specific CD4+ and CD8+ T-cell responses
JP2018517419A5 (cg-RX-API-DMAC7.html)
Zhao et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
RU2019125436A (ru) Новый подход к иммунотерапии, нацеленной на vegfr-2
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
BR112021001117A2 (pt) células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas
CN110408634B (zh) 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
Menezes et al. Prospects of gene therapy to treat melanoma
Riederer et al. Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease
Jia et al. The future of cancer vaccines against colorectal cancer
Kim et al. Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism
EP2826856A1 (en) Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
Bella et al. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
Sun et al. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy